The liver kinase B1 (LKB1)/adenosine mono-phosphateactivated protein kinase (AMPK)/tuberous sclerosis complex (TSC)/mammalian target of rapamycin (mTOR) complex (mTORC1) cassette constitutes a canonical signaling pathway that integrates information on the metabolic and nutrient status and translates this into regulation of cell growth. Alterations in this pathway are associated with a wide variety of cancers and hereditary hamartoma syndromes, diseases in which hyperactivation of mTORC1 has been described. Specific mTORC1 inhibitors have been developed for clinical use, and these drugs have been anticipated to provide efficient treatment for these diseases. In the present review, we provide an overview of the metabolic LKB1/AMPK/TSC/mTORC1 pathway, describe how its aberrant signaling associates with cancer development, and indicate the difficulties encountered when biochemical data are extrapolated to provide avenues for rational treatment of disease when targeting this signaling pathway. A careful examination of preclinical and clinical studies performed with rapamycin or derivatives thereof shows that although results are encouraging, we are only half way in the long and winding road to design rationale treatment targeted at the LKB1/ AMPK/TSC/mTORC1 pathway. Inherited cancer syndromes associated with this pathway such as the PeutzJeghers syndrome and TSC, provide perfect models to study the relationship between genetics and disease phenotype, and to delineate the complexities that underlie translation of biochemical and genetical information to clinical management, and thus provide important clues for devising novel rational medicine for cancerous diseases in general.
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The liver kinase B1 (LKB1)/adenosine mono phosphate activated protein kinase (AMPK)/tuberous sclerosis complex (TSC)/mammalian target of rapamycin (mTOR) complex 1 (mTORC1) signaling pathway signaling pathway is central in regulating cellular metabolism and cell growth by integrating information regarding the intracellular energy and oxygen status, the presence of growth factors and nutrient availability. Under circumstances of sufficient energy and nutrient sources, this metabolic pathway stimulates cell growth. In cases of stress, metabolic processes are adjusted to restore resources in the cell.
LKB1/AMPK signaling LKB1 (also referred to as serine/threonine kinase 11) is a 50 kDa serine/threonine kinase and is ubiquitously expressed in adult and fetal tissues, particularly in pancreas, liver, testes and skeletal muscle (Hemminki et al., 1998; Jenne et al., 1998) . Lacking a nuclear export domain of its own, in the absence of stimulation, LKB1 is retained in the nucleus in an inactive state (Figure 1 ). Activation of LKB1 is associated with its translocation to the cytoplasm, which is induced upon formation of a heterotrimer with the STE20-related adaptor protein a (STRADa) and scaffolding mouse 25 protein (MO25) Boudeau et al., 2003; Brajenovic et al., 2004) (Figure 1) . By facilitating the binding of exportins to LKB1 and acting as a competitor for importin-a/b, STRADa prevents nuclear re-localization of LKB1 (Dorfman and Macara, 2008) (Figure 1 ). MO25 merely serves as a stabilizer of the LKB1-STRADa interaction . In addition to inducing its translocation, LKB1-STRADa interaction also results in LKB1 (auto) phosphorylation at various residues. However, the functional relevance of this remains debatable, as prevention of phosphorylation does not appear to affect LKB1 kinase activity (Jansen et al., 2009) .
When activated, LKB1 phosphorylates and activates AMPKa and its related serine/threonine kinases ( Figure 1 ) (Hawley et al., 2003; Lizcano et al., 2004; Shaw et al., 2004; Jaleel et al., 2005; Lim et al., 2010) . Via the regulation of MARK isoforms and PAR proteins, LKB1 establishes cell polarity (Figure 1 ) (Spicer et al., 2003; Lizcano et al., 2004) . AMPKa is activated by LKB1 in response to energy stress. When, due to either excessive ATP consumption or in the case of hypoxia, reduced aerobic ATP production, cellular AMP/ATP ratios are increased ( Figure 2 ). This is sensed by AMPK, which through binding of AMP undergoes a conformational change, upon which it can be phosphorylated by LKB1 (Figure 2 ) (Alessi et al., 2006; Hardie, 2007; Jansen et al., 2009) . AMPKa can also be phosphorylated by calcium/calmodulin-dependent protein kinase kinase, which is triggered through influx of calcium ( Figure 2 ) (Hawley et al., 1995) . The phosphorylation of AMPKa is reversed by the phosphatases PP2A and PP2C (Figure 2 ) (Moore et al., 1991) .
LKB1/AMPK signaling induces several cellular processes, one of which is the control of energy metabolism through regulation of several downstream targets, including the metabolic enzymes acetyl-CoA carboxylase and HMG-CoA reductase (Figure 2) (Carling et al., 1987) . By suppressing energy-consuming processes such as glycogen and lipid synthesis on the one hand, and enhancing energy-gaining pathways such as glycolysis on the other, AMPK activation aids in restoration of the cellular energy status (Kola et al., 2006) . In line, AMPK activation induces relocalization of the glucose importer GLUT4 to the plasma membrane (Figure 2 ) (Kurth-Kraczek et al., 1999) . In addition, LKB1/AMPK signaling regulates factors involved in cell cycle regulation, survival and gene transcription (Figure 2) (Jansen et al., 2009; Shackelford and Shaw, 2009 ). One of the downstream effectors of AMPK is TSC2 as described in more detail below. In conclusion, LKB1/AMPK signaling serves to coordinate energy metabolism, cell polarity and cell growth, processes which are all crucial in the development of cancer.
Regulation of the TSC1:TSC2 complex The TSC1:TSC2 complex exists as a heterodimer of two proteins, the 130 kDa TSC1 (also referred to as hamartin) and the 200 kDa TSC2 (also referred to as tuberin) (Huang and Manning, 2008) . TSC1 and TSC2 are widely expressed in human tissues, such as heart, brain, lung, liver, kidney, pancreas and skeletal muscle (Consortium, 1993; van Slegtenhorst et al., 1997; Huang and Manning, 2008) . The two proteins interact through coiled-coil domains to form a stable, functional heterodimer (van Slegtenhorst et al., 1998) . The C-terminal region of TSC2 shows homology to the Rap GTPase activating protein, and GTPase activating protein activity to various G-proteins (Wienecke et al., 1995; Xiao et al., 1997 NUAK1, NUAK2  SIK1, SIK2  QSK  MARK1, MARK2, MARK3, MARK4  BRSK1, BRSK2  SNRK inactive active p la s m a m e m b r a n e Figure 1 Activation and translocation of LKB1. LKB1 is activated by its translocation from the nucleus to the cytoplasm. Normally, LKB1 remains in the nucleus in an inactive state. Upon activation, LKB1 is bound by STE20-related adaptor protein a (STRADa) and mouse protein 25 (MO25), proteins that enter the nucleus either by passive diffusion or active import by importins a/b (Impa, Impb). The stable LKB1/STRADa/MO25 complex is actively exported out of the nucleus by exportin 7 and CRM1. In the cytoplasm, LKB1 exerts its serine/threonine kinase activity by phosphorylating and activating the 14 members of the AMPK serine/threonine kinase family regulating cell polarity, energy metabolism and cell growth. AMP is bound by the AMP-dependent protein kinase g subunit (AMPKg), which forms a complex with AMPKa and -b. Upon formation of this complex, AMPKa is phosphorylated by LKB1. AMPKa can also be phosphorylated by calcium/calmodulindependent protein kinase kinase (CaMKK) and is dephosphorylated by the protein phosphatases PP2A and PP2C. The activated AMPK complex induces translocation of the glucose importer GLUT4 to the plasma membrane to enhance glucose uptake and regulates downstream signaling controlling gene transcription and metabolic processes. Together, this results in the restoration of the energy balance in the cell.
Road to treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling W van Veelen et al catalytic domains of its own but merely functions by preventing ubiquitin-mediated degradation of TSC2, thereby stabilizing intracellular TSC2 expression levels to maintain TSC2 activity (Benvenuto et al., 2000; Chong-Kopera et al., 2006) . Regulation of the TSC1:TSC2 complex is mainly achieved by phosphorylation. Although phosphorylation of TSC1 inhibits the complex, phosphorylation of TSC2 can either inhibit or activate TSC1:TSC2 activity (Figure 3 ) (Orlova and Crino, 2010) . AMPK activates the TSC1:TSC2 complex by phosphorylating TSC2 on Thr1227 and Ser1345 in metabolic stress (Figure 3 ) (Inoki et al., 2003) . Recently, the phosphorylation on Ser1345 has been shown to prime TSC2 for additional phosphorylation by GSK3b, which may be required for full activation of TSC2 . As an alternative to AMPK-induced activation of the TSC1:TSC2 complex, hypoxia-induced metabolic stress causes increased transcription of REDD, which also results in TSC2 activation (Figure 3) (Sofer et al., 2005) . In contrast to these stress-induced TSC1:TSC2 complex activation pathways, various growth factors and cytokines inhibit activation of the TSC1:TSC2 complex by inhibitory phosphorylation of TSC1 or TSC2 through PI3K/PKB (also known as AKT), ERK/RSK or IKKb signaling modules (Figure 3 ) (Hay and Sonenberg, 2004; Inoki et al., 2005; Bhaskar and Hay, 2007; Huang and Manning, 2008) . Phosphorylation of TSC2 by these kinases usually results in dissociation of the TSC1:TSC2 complex, followed by its degradation (Orlova and Crino, 2010) . Thus, the TSC1:TSC2 complex integrates information on the available intra-and extracellular resources, and translates this into cell growth.
TSC/mTORC1 signaling The activated TSC1:TSC2 complex regulates the activity of the mTORC1, a complex consisting of mTOR, raptor and mLST8. Therefore, the TSC1:TSC2 complex expresses GTPase activating protein activity towards Rheb, a small G-protein that promotes mTORC1 activity when GTP-bound (Figure 4) 
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Figure 4 TSC/mTORC1 signaling. The mTOR complex 1 (mTORC1), consisting of mTOR, raptor and mLST8, controls cell growth mainly through the regulation of protein translation. Activated TSC1:TSC2 complex expresses GTPase activating protein activity towards Rheb, thereby inducing conversion of active GTP-bound Rheb to inactive GDP-bound Rheb. Active Rheb promotes mTORC1 activation, controlling protein translation by activating the ribosomal protein S6 kinase (S6K), inhibiting inhibition eukaryotic initiation factor 4E binding proteins (4E-BP) and inhibiting the RNA polymerase III (PolIII) repressor MAF1. In addition, mTORC1 induces angiogenesis through induction of hypoxia-inducible factor 1a (HIF1a)-dependent expression of vascular endothelial growth factor (VEGF), and inhibits autophagy by phosphorylating ATG13 and ULK1/2. In addition to TSC-dependent regulation of mTORC1 activity, the complex is directly activated by sufficient levels of energy (ATP) and nutrients (amino acids), as well as through phosphorylation of mTOR by PKB and of raptor by AMPK.
Road to treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling W van Veelen et al 2003b). The activated TSC1:TSC2 complex induces conversion of active GTP-bound Rheb to inactive GDP-bound Rheb, which subsequently results in inhibition of mTORC1 (Figure 4) (Zhang et al., 2003b) . In addition to the TSC1:TSC2-mediated inhibition of mTORC1, various metabolic factors such as ATP and amino acids regulate mTORC1 independent of the TSC1:TSC2 complex (Figure 4) (Dennis et al., 2001; Hay and Sonenberg, 2004) . Furthermore, mTORC1 activity can be affected by direct phosphorylation of its components by several kinases that also directly phosphorylate TSC1:TSC2. For example, direct phosphorylation of mTOR by PKB, and of raptor by AMPK have been shown to regulate mTORC1 activity (Figure 4 ) (Vander Haar et al., 2007; Gwinn et al., 2008) .
Upon activation, the mTORC1 controls cell growth by regulating protein translation by phosphorylating and activating the ribosomal protein S6 kinase (S6K), and through the inhibition of eukaryotic initiation factor 4E binding proteins (4E-BPs) (Figure 4 ) (Hara et al., 2002; Kim et al., 2002) . Recently, it has been shown that mTORC1 directly phosphorylates MAF1, thereby releasing its repressive action on RNA polymerase III leading to increased protein translation ( Figure 4 ) (Kantidakis et al., 2010; Michels et al., 2010) . In addition, activation of mTORC1 stimulates angiogenesis by inducing hypoxia-inducible factor 1a, which increases the expression of vascular endothelial growth factor (Figure 4 ) (Hudson et al., 2002) . Furthermore, mTORC1 activity inhibits autophagy via phosphorylation of ATG13 and ULK1/2 ( Figure 4 ) (Hosokawa et al., 2009; Jung et al., 2009) . As these processes are all essential in tumorigenesis, it is not surprising to observe that deregulation of the LKB1/ AMPK/TSC/mTORC1 signaling pathway is frequently associated with human cancer.
LKB1/AMPK/TSC/mTORC1 signaling in disease
Through specific genetic alterations in different components of the LKB1/AMPK/TSC/mTORC1 signaling pathway, this metabolic pathway is associated with disease ( Figure 5 ). Mutations in or loss of the tumor suppressors PTEN or neurofibromatosis type 1 (NF1) result in the activation of the PI3K/PKB or RAS/ERK signaling modules, respectively, which both subsequently inhibit the TSC1:TSC2 complex. In addition, inactivation of the tumor suppressor LKB1 leads to impaired activation of AMPK and the TSC1:TSC2 complex in metabolic stress conditions. Furthermore, the TSC1:TSC2 complex can be inactivated by mutations in its own encoding tumor suppressor genes. Together, these genetic alterations result in hyperactivation of the mTORC1-mediating downstream signaling, which induces cell growth.
Germ-line inactivation of the tumor suppressor genes PTEN, NF1, LKB1, TSC1 and TSC2 predisposes to a group of rare autosomal dominant inherited hamartoma syndromes ( Figure 5 ). These hereditay disorders are characterized by the development of hamartomas in multiple tissues (Table 1) . Hamartomatous polyps have a relatively benign appearance, but with a markedly disturbed architecture of cells present in the area in which they normally occur, that is, mesenchymal, stromal, endodermal, and ectodermal (Calva and Howe, 2008) . Hamartomatous polyps are clearly distinct from the more common adenomatous polyps, which are premalignant lesions characterized by a dysplastic epithelium ('adenoma-to-carcinoma sequence'). In contrast, the overlying epithelium in hamartomatous polyps is usually well differentiated but can be hyperplastic, and therefore, the malignant potential of hamartomas is still controversial. Despite the fact that these hamartomas follow a relatively benign course, they can cause, for example, bowel obstruction, seizures or hemorrhage, which may lead to severe complications and even death (Calva and Howe, 2008) . In addition to the development 
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Figure 5 LKB1/AMPK/TSC/mTORC1 signaling in hamartoma syndromes. Genetic alterations in the LKB1/AMPK/TSC/ mTORC1 pathway are involved in several hereditary hamartoma syndromes. Germ-line inactivation of the tumor suppressor PTEN, which normally inhibits PI3K/PKB signaling, predisposes to a variety of hamartoma syndromes grouped as PTEN hamartoma tumor syndromes. Germ-line inactivation of the tumor suppressor NF1, an inhibitor of the RAS/ERK pathway, predisposes to NF1. Germ-line inactivation of the tumor suppressor LKB1, the activator of AMPK, predisposes to the PJS. Germ-line inactivation of the tumor suppressors TSC1 or TSC2, both predisposes to TSC. The genetic alterations associated with these hamartoma syndromes, all result in the inactivation of the TSC1:TSC2 complex causing impaired inhibition of mTORC1 leading to enhanced cell growth. Therefore, mTORC1 serves as an ideal target to be inhibited in order to treat patients suffering from these hamartoma syndromes. The pharmacological inhibitor rapamycin (and its analogs everolimus and temserolimus) forms an inhibitory complex with its intracellular receptor, FK506-binding protein (FKBP12), which binds mTOR thereby causing a dissociation and inhibition of mTORC1. Tumor suppressors are indicated in white.
Road to treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling W van Veelen et al of multiple hamartomas, these polyposis syndromes are associated with the development of a variety of cancers as well. In addition, somatic alterations in genes involved in the LKB1/AMPK/TSC/mTORC1 pathway have been associated with a wide variety of sporadic human cancers.
Tumor suppressor gene LKB1 and cancer Inactivating LKB1 mutations are detected in 5-17% of sporadic non-small cell lung carcinomas and in 5% of pancreatic cancers and melanomas. Promoter hypermethylation or loss of LKB1 expression has been described for sporadic testicular, papillary breast, endometrial, neuroendrocrine lung and pancreatic cancer . Germ-line mutations in LKB1 predispose to the Peutz-Jeghers syndrome (PJS), (Hemminki et al., 1998; Jenne et al., 1998) which is characterized by mucocutaneous hyperpigmentation, gastrointestinal hamartomatous polyposis and a highly increased risk for developing gastrointestinal, breast, gynecological and lung cancer (Tomlinson and Houlston, 1997; McGarrity and Amos, 2006; van Lier et al., 2010) (Table 1) . LKB1 is classified as a tumor suppressor gene implying that both alleles need to be inactivated to induce tumor development. Loss of heterozygosity of the remaining LKB1 allele has been detected in a subset of PJS-hamartomas, however, it is observed more frequently in carcinomas. Around 150 different mutations without a hotspot in LKB1 have been associated with PJS, without a clear genotype-phenotype correlation, have been detected (Yoo et al., 2002) . The majority of mutations results in truncation or abnormal splicing, although in B20% of the cases, a missense mutation in the kinase domain of LKB1 is detected. The truncating mutations tend to associate with an earlier age of onset of disease as compared with PJS cases associated with missense mutations in LKB1 (Yoo et al., 2002) . The effect of most PJS-associated missense mutations on LKB1 function has not yet been investigated.
To investigate the tumor suppressor function of LKB1, mouse models have been generated and characterized. Homozygous loss of Lkb1 is embryonically lethal, whereas mice with a heterozygous deletion are tumor prone, showing an increased incidence of spontaneous tumor formation as well as increased susceptibility to toxicity-induced carcinogenesis (Ylikorkala et al., 2001; Jishage et al., 2002; Miyoshi et al., 2002; Gurumurthy et al., 2008) . Moreover, Lkb1 þ /À mice develop hamartomatous polyps in the stomach and intestines, but, similar to their human counterparts, these polyps appear to lack or have only low malignant potential (Jishage et al., 2002; Miyoshi et al., 2002) . Interestingly, heterozygous loss of Lkb1 in Road to treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling W van Veelen et al myofibroblasts has been shown to be sufficient to induce hamartoma formation in mice, indicating that these stromal cells are the driving force of hamartomas, and that LKB1 can function as a haploinsufficient tumor suppressor (Katajisto et al., 2008) . Finally, conditional Lkb1 loss in various tissues is also associated with the development of cancer (Contreras et al., 2008; Pearson et al., 2008; McCarthy et al., 2009 ).
In conclusion, the phenotypes observed in human patients and mouse models indicate that loss of LKB1 activity is involved in the development of a variety of cancers.
Tumor suppressor genes TSC1 and TSC2 and cancer Inactivating mutations in TSC1 and TSC2 are detected mainly in sporadic renal cell carcinomas (RCCs) (Knowles et al., 2003) . Loss of chromosome 16p (locus for TSC2) or promoter hypermethylation of the TSC genes has been detected in a substantial proportion of ovarian, gall bladder and breast cancer (Knowles et al., 2003; Jiang et al., 2005) . Germ-line mutations in TSC1 and TSC2 predispose to TSC (Consortium, 1993; van Slegtenhorst et al., 1997) , which is characterized by the development of widespread hamartomas in several organs including brain (cortical tubers and subependymal glial nodules), kidneys (angiomyolipomas, AML), skin ((angio) fibromas), heart (rhabdomyomas) and lungs (lymphangioleiomyomatosis (LAM)) ( Table 1 ). In addition, these patients develop early onset brain cancer (subependymal giant cell astrocytomas (SEGAs)) and different types of renal cancer (Table 1) (Schwartz et al., 2007; Curatolo et al., 2008; Ess, 2010) . Notably, LAM also occurs sporadically, owing to somatic mutations in the TSC genes, and is associated with renal AML in B50% of these cases (Carsillo et al., 2000) .
Both TSC genes are characterized as tumor suppressor genes and loss of function of either gene leads to hamartoma formation. Loss of heterozygosity in affected organs is frequently detected in combination with TSC2 mutations, but only rarely with mutations in TSC1. Genetic studies have revealed large deletions and missense mutations in TSC2, whereas the majority of mutations in TSC1 are small and result in expression of a truncated protein. No mutational hotspots in either TSC1 or TSC2 have been identified. In fact, over 300 different mutations have been described for TSC1, and even over a 1000 for TSC2, probably contributing to the clinical variability observed among TSC patients. Although a clear genotype-phenotype correlation has not been identified for TSC, TSC2 mutations are associated with a more severe disease phenotype compared with TSC1 mutations (Sancak et al., 2005) .
The tumor suppressor functions of TSC1 and TSC2 have been studied using animal models. In mice, homozygous loss of either Tsc1 or Tsc2 result in embryonic lethality, whereas in heterozygous animals increased tumor formation including renal cystadenomas, and learning deficits are apparent (Rennebeck et al., 1998; Kobayashi et al., 1999; Kwiatkowski et al., 2002) . Additionally, epilepsy, brain malformations, RCCs and additional tumors have been described in Eker rats, which have a naturally occurring inactivating Tsc2 mutation (Cook and Walker, 2004; Hino, 2004; Yeung, 2004) . Epilepsy and brain abnormalities were also detected in mice with a specific Tsc1 deletion in cells of the neuronal system (Uhlmann et al., 2002) .
Together, these observations indicate that loss of a functional TSC1:TSC2 complex contributes to the development of a variety of benign and malignant tumors.
Genetic alterations in other components of the LKB1/ AMPK/TSC pathway and cancer PI3K/PKB signaling, which is counteracted by the lipid phosphatase PTEN, modulates LKB1/AMPK/TSC/ mTORC1 signaling and activates the mTORC1 directly or via inhibiting the TSC1:TSC2 complex (Figures 3  and 4) . Thus, activation of the PI3K/PKB signaling cassette by genetic alterations in PTEN, PIK3CA or PKB result in activation of mTORC1 signaling and is associated in different types of human cancer (Sansal and Sellers, 2004) . Somatic inactivating mutations in the tumor suppressor gene PTEN are frequently detected in glioblastomas, melanomas, and in prostate and endometrial cancers (Sansal and Sellers, 2004) . Loss of PTEN expression has been observed in sporadic hepatocellular carcinomas (Villanueva et al., 2008) .
In addition to inactivation of PTEN, activation of PI3K or PKB is observed in several types of sporadic human cancer. Activation of PI3K has been described for ovarian, gastric, head and neck squamous cell carcinomas (by amplification of PIK3CA), and for gastric, colorectal and mammary carcinomas, and glioblastomas (by somatic missense mutations in PIK3CA) (Altomare and Testa, 2005). Amplification, overexpression or activation of PKB has been observed in ovarian, pancreatic, hepatocellular, mammary, prostate and colorectal carcinomas (Altomare and Testa, 2005) . In neuroendocrine tumors (NETs), derived from neuroendocrine cells scattered throughout the body, for example, in the pancreas, stomach, (para) thyroid and pituitary glands, overexpression of PKB and decreased expression of TSC2 and PTEN has been observed (Dworakowska and Grossman, 2009; Missiaglia et al., 2010) . NETs have even been suggested to be a clinical feature of TSC (Dworakowska and Grossman, 2009) .
Inactivating germ-line mutations in PTEN predispose to a variety of different hereditary syndromes, such as Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, proteus syndrome and Lhermitte-Duclos disease, which have been proposed to be grouped together as PTEN hamartoma tumor syndromes (PHTS), all characterized by the formation of hamartomas and cancerous lesions (Table 1) (Sansal and Sellers, 2004) .
Another modifier of the LKB1/AMPK/TSC/ mTORC1 pathway, which is also associated with hamartoma and cancer development is NF1. NF1 encodes neurofibromin, which activates Ras-GTPase. Accordingly, in NF1-deficient tumors, Ras is hyperactivated, which, in addition to other downstream Road to treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling W van Veelen et al pathways, activates mTORC1 signaling. Germ-line inactivation of NF1 results in NF1, which is characterized by the development of benign (neurofibromas) and malignant peripheral nerve sheath tumors and hamartomatous lesions of the iris (Table 1) (Parrinello and Lloyd, 2009 ).
The LKB1/AMPK/TSC module constitutes a canonical signal transduction pathway controlling mTORC1 activity whose importance for the integration of cellular nutritional status and survival signaling to external cues is undisputed. However, the disease phenotypes related to genetic alterations within this pathway are highly heterogeneous, and show no overlap. The knowledge on molecular biology and biochemistry has provided us with a linear view on signaling pathways and the responses due to alterations in these pathways. On the other hand, these genetic disorders show the importance of external modifiers of the pathway for final clinical outcome in the context of complex systems like living organisms. Why aberrant LKB1/AMPK/TSC signaling results in these highly tissue-specific disease phenotypes is not yet completely understood, but may be due to the high level of biological robustness of the pathway. For example, it induces feed-forward inhibition through the transcription of miR451, which in turn downregulates the activity of the entire cassette (Godlewski et al., 2010) . In addition, signaling thresholds, the presence of redundant enzymes and feed-back mechanisms lead to a highly complex system of biochemical interaction whose outcome shows a great deal of cell type and contextdependent specificity.
Hyperactive mTORC1 in LKB1/AMPK/TSC-associated lesions
As described above, various lesions are associated with alterations in the metabolic LKB1/AMPK/TSC signaling pathway. As inactivation of this signaling cassette impairs the inhibition of mTORC1, it is anticipated that lesions associated with LKB1/AMPK/TSC inactivation show enhanced mTORC1 activity. The activation status of mTORC1 is commonly determined by the phosphorylation of its downstream effectors S6K, the ribosomal protein S6 and/or 4E-BP (Figure 4) .
The mTorc1 hyperactivation has indeed been observed in Lkb1-null mouse embryonic fibroblasts as well as in other murine and human LKB1-deficient cells (Corradetti et al., 2004; Shaw et al., 2004 Shaw et al., , 2005 Carretero et al., 2007; Contreras et al., 2008; Ikeda et al., 2009 ). In addition, mTorc1 hyperactivation has been observed in intestinal polyps of Lkb1 þ /À mice and PJS patients, indicating that mTORC1 is hyperactivated in PJS-associated hamartomas (Shaw et al., 2004; Shackelford and Shaw, 2009 ). Whether mTORC1 is hyperactivated in PJS-associated carcinomatous lesions as well, is yet to be determined.
In Tsc1-and Tsc2-null mouse embryonic fibroblasts as well as in other Tsc-deficient cells, increased mTorc1 activity has been detected Onda et al., 2002; Zhang et al., 2003a; Uhlmann et al., 2004; Habib et al., 2010) . In skin fibroblasts of TSC patients, and in TSC2-deficient AML cells from a patient with LAM, mTORC1 hyperactivation has been detected (Jozwiak et al., 2009; Lee et al., 2010) . In addition, in renal cystadenomas from Tsc1-and Tsc2-deficient mice Zhang et al., 2003a) , as well as in surgically resected tubers, SEGAs and AMLs from TSC patients, increased levels of phospho-S6 could be detected, indicating that mTORC1 is hyperactivated in TSC-associated lesions (El-Hashemite et al., 2003; Baybis et al., 2004; Chan et al., 2004; Miyata et al., 2004) .
Additionally, downstream mTORC1 signaling has been shown to be active in Nf1-and Pten-deficient cells (Podsypanina et al., 2001; Johannessen et al., 2008) . Hyperactivation of mTORC1 have further been established for RCC cell lines and tumors as well as for various NET cell lines and animal models (Chan et al., 2010) , and in B50% of hepatocellular carcinomas (Villanueva et al., 2008) . Together, the observed exaggerated activation of mTORC1 in these LKB1/ AMPK/TSC-associated lesions suggests that mTORC1 would serve an effective target for therapy to treat these cancerous and hamartomatous lesions.
Treatment of LKB1/AMPK/TSC-associated lesions with mTORC1 inhibitors
Rapamycin and analogs as anticancer drugs Rapamycin, also known as sirolimus, is a macrolide antibiotic first discovered in the 1970's on Easter Island as a product of the bacterium Streptomyces hygroscopicus Vezina et al., 1975) , and has been identified as an effective inhibitor of mTORC1 (Heitman et al., 1991) . Rapamycin forms an inhibitory complex with the cytosolic FK-binding protein-12. Binding of this complex to the mTOR protein results in the dissociation of mTORC1, thereby inhibiting its ability to phosphorylate downstream substrates ( Figure 5 ) (Chung et al., 1992) . Due to its ability to inhibit T-and B-cell proliferation and activation (Dumont et al., 1990; Wicker et al., 1990) , rapamycin and its analogs RAD001 (everolimus) and CCI-779 (temsirolimus) have been approved by the Food and Drug Administration (FDA) as immunosuppressive agents in the United States, and is now commercially available. In addition, these drugs appear to affect tumor growth by inducing tumor cell apoptosis and suppressing angiogenesis (Law, 2005) . Temsirolimus (in May 2007) and everolimus (in March 2009) have been FDA approved for the treatment of advanced RCC after failure of first-line treatment with sunitinib or sorafenib. Only very recently, in October 2010, the FDA approved the use of everolimus also for the treatment of TSC-associated SEGAs that can not be surgically removed. Currently, several phase III trials testing the efficacy of rapamycin and its analogs are ongoing for a variety of malignancies such as breast, gastric and hepatocellular cancer, mantle cell lymphoma and cancers associated with transplantation (http://www.clinicaltrials.gov). Preclinical studies show that everolimus is able to inhibit proliferation of several NET cell lines, and ongoing clinical trials investigating the use of everolimus for the treatment of sporadic NETs provide evidence that the drug is able to reduce tumor size and control disease progression (Chan et al., 2010) .
Thus, rapamycin analogs are approved anticancer drugs, and their efficacy in the treatment of a variety of sporadic cancers is currently being tested.
The mTORC1 inhibitors as treatment for hamartoma syndromes Previously, it has been shown that rapamycin is able to inhibit mTorc1 signaling in Lkb1-deficient cells (Shaw et al., 2004) . Preclinical evaluation of the suppressive and preventive efficacy of rapamycin for PJS using Lkb1 þ /À mice has revealed that rapamycin effectively reduced the tumor burden in these animals (Wei et al., 2008 (Wei et al., , 2009 Robinson et al., 2009; . Also in mouse models for NF1 and PHTS, treatment with rapamycin has been shown to reduce tumor growth (Podsypanina et al., 2001; Hegedus et al., 2008; Squarize et al., 2008) . At present, one open-label phase II clinical trial is recruiting PJS patients for suppressive therapy with everolimus to determine if this drug can diminish gastrointestinal polyps (clinicaltrials. gov identifier NCT00811590). Another phase II trial recruiting PJS patients with advanced cancer is currently active (clinicaltrials.gov identifier NCT01178151). Four clinical phase I/II trials are ongoing including NF1 patients to test the safety and efficacy of rapamycin and everolimus to treat gliomas, cutaneous fibromas and neurofibromas in these patients (clinicaltrials.gov identifiers NCT01158651, NCT01031901, NCT00634270, NCT00652990). To test the efficacy of rapamycin to treat patients with Cowden syndrome and other PTEN-associated syndromes, one clinical phase II trial is currently ongoing (clinicaltrials.gov identifier NCT00971789). Preclinical and clinical studies evaluating the efficacy of rapamycin and analogs for the treatment of lesions associated with TSC are described in more detail below.
The mTORC1 inhibitors as treatment for TSC
Preclinical studies have demonstrated the ability of rapamycin to inhibit mTORC1 activity and cell growth in murine and human TSC1-or TSC2-deficient cells Onda et al., 2002; Zhang et al., 2003a; Uhlmann et al., 2004; Jozwiak et al., 2009; Mi et al., 2009; Habib et al., 2010; Lee et al., 2010) . In vivo, rapamycin treatment reduced the tumor burden and increased survival in TSC-deficient animal models developing renal tumors (Kenerson et al., 2005; Lee et al., 2005 Lee et al., , 2006 Pollizzi et al., 2009; Woodrum et al., 2010) .
The first case report of rapamycin-therapy for TSCassociated tumors in patients has been published in 2006 (Franz et al., 2006) . Four TSC-patients with SEGAs and one with a pilocytic astrocytoma were treated with oral rapamycin at standard immunosuppressive doses (serum levels 5-15 ng/ml) for 2.5-20 months. During follow-up, neuroimaging showed regression of all lesions, and necrosis could be observed in one case. Known side effects of rapamycin such as aphthous ulcers, acneiform rash and elevation of serum cholesterol were reported. In one patient, discontinuation of therapy led to the increase of SEGAs, and subsequent regression after reintroduction of rapamycin. Since then, a number of additional case reports have been published on this topic ( Table 2) .
The results of the first formal prospective phase I/II open-label clinical trial of sirolimus therapy for patients with TSC or sporadic LAM, in which both are associated with AML development, were published in 2008 (Bissler et al., 2008) . A cohort of 25 adult patients, 19 with TSC (of who 12 had LAM) and 6 with sporadic LAM, were treated with sirolimus (5-15 ng/ml) for 1 year, followed by a 12-month follow-up period. Evaluation after 1 year of therapy showed a reduction in AML volume of at least 30% in 16 of 20 patients (including 14 TSC patients). However, during the year of follow-up after cessation of therapy, AML regrowth occurred in 17 of 18 patients completing the trial. Furthermore, effects on pulmonary function were elusive, and no effect on cortical tuber size could be detected. Simultaneously, interim findings of another, ongoing phase II trial were revealed (Table 3 , clinicaltrials.gov identifier NCT00490789) (Davies et al., 2008) . Although a decrease of AML size could be detected in all included patients, no significant improvement in lung function was observed. In both trials, a high rate of adverse events of sirolimus therapy was reported, though they were mostly low-grade and self-limiting.
Recently, the results of an open-label study investigating the use of everolimus for SEGAs in young TSC patients (age X3 years) have been published (Krueger et al., 2010) . Twenty-eight patients (median age 11 years, 22 under 18 years of age) had been treated with everolimus at a dose of 3.0 mg/m 2 . In the majority of patients (75%), therapy was associated with a clinically meaningful reduction in SEGA volume of at least 30% at 6 months. The decrease in tumor volume was most obvious during the initial 3 months of treatment after which a sustained response could be observed. In one patient, after regression of SEGA volume at 6 months of therapy, progression of tumor volume had been detected. All patients included in this study had at least one adverse event during everolimus therapy, of which four were of serious nature. At present, a number of formal clinical trials of mTORC1 inhibitors for the treatment of TSC-associated manifestations are ongoing (Table 3 ) (clinicaltrials.gov).
Together, this indicates that in addition to RCC, and TSC-associated SEGAs, rapamycin treatment may be beneficial for other LKB1/AMPK/TSC/mTORC1-associated sporadic cancers and hereditary hamartoma syndromes as well. However, several concerns can be raised for rapamycin as an anticancer drug as can be learned from the studies described above. Although promising effects for sporadic and TSC-associated renal Road to treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling W van Veelen et al Case 1: rapamcyin 6 mg (7.7 ng/ml). Case 2: rapamycin 7 mg (10.9 ng/ml)/lamotrigine, phenobarbital. Case 3: rapamycin 4 mg (10.2 ng/ml). Case 4: rapamycin 5 mg (9.6 ng/ml)/divalproex sodium, clonidine, quetiapine and amitriptyline.
Case 5: rapamycin 6 mg (10.4 ng/ml) Road to treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling W van Veelen et al AMLs and cutaneous angiofibromas are observed, after initial reduction of lesion sizes, the disease stabilizes when the treatment is continuated over 1 year. Total regression of lesions due to rapamycin therapy has never been observed, except for facial angiofibromas and erythema treated with topical administration of sirolimus (Kaufman McNamara et al., 2010) . In fact, tumor regrowth occurred following cessation of therapy (Franz et al., 2006; Wienecke et al., 2006; Bissler et al., 2008) . These observations would implicate a life-long treatment with rapamycin, but little is known yet about long-term effects or complications of the drug. Moreover, it is unclear whether the reduction of AML size upon rapamycin treatment is associated with a reduced risk of hemorraghic complications of these tumors, the leading cause of mortality in TSC patients. To date, no clear effect of mTORC1 inhibition on cortical tubers in TSC patients has been demonstrated. In contrast, a slightly increased number of cortical tubers in a female patient after renal transplantation has been observed after 2 years of rapamycin treatment (Tarasewicz et al., 2009) . This suggests that rapamycin would not be an effective drug to treat TSC-associated epilepsy and autism, which is believed to be caused by these cortical tubers. It has been suggested that these brain malformations are dysplastic rather than neoplastic, which might explain why they are not responsive to the anti-proliferative effect of rapamycin (Bissler et al., 2008) . However, pre-clinical studies in several mouse models showed improvement in neurological manifestations of TSC, such as seizures, and memory and learning deficits (Ehninger et al., 2008; Meikle et al., 2008; Zeng et al., 2008) . Furthermore, reduced seizure frequencies in TSC patients have been described upon treatment with rapamycin (Franz et al., 2006; Muncy et al., 2009) . The effect of everolimus on epileptic seizure frequency in patients with TSC (aged 2 years and older) is currently investigated in a clinical trial (Table 3 ) (clinicaltrials.gov identifier NCT01070316).
Synopsis
Modulation of the LKB1/AMPK/TSC signaling pathway by environmental factors and genetic alterations results in aberrant mTORC1 signaling, which is observed in a wide variety of benign and malignant tumors. The distinct phenotypes associated with this aberrant signaling are difficult to interpret, however, the overall observation that mTORC1 is hyperactivated in Regression of SEGAs after 3, 6 and 11 months of treatment. Stabilization of SEGAs after 10 months discontinuation of treatment.
Abbreviations: AML, angiomyolipomas; CPK, creatine phosphokinase; FU, follow-up; GFR, glomerular filtration rate; NR, not reported; RCC, renal cell carcinoma; SEGA, subependymal giant cell astrocytoma; TSC, tuberous sclerosis complex.
Road to treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling W van Veelen et al these tumors provides hope that rationale approaches by using mTORC1 inhibitors may indeed meet clinical success. The anti-inflammatory and anti-angiogenic properties of rapamycin and its analogs are useful here, as it is well known that both inflammation and angiogenesis are linked with carcinogenesis through various mechanisms (for example, (Law, 2005; Massoumi and Sjolander, 2007) ). The success of rapamycin treatment in cancer depends on the addiction to mTORC1 activity for the tumor cells to expand. As LKB1, PTEN and NF1 are proteins a few steps upstream of the mTORC1 complex, loss of these proteins changes signaling not only leading to enhanced mTORC1 activation but also regulating mTORC1-independent signaling modules enhancing cell survival and proliferation. Therefore, these cells may be insensitive to pharmacological inhibition of mTORC1. This could be circumvented by the use of pharmacological agents affecting signaling upstream of mTORC1. For example, sorafenib, a RAF inhibitor, which inhibits the activation of ERK, is an FDA approved drug for the treatment of advanced RCC and hepatocellular carcinoma. Several PI3K/PKB inhibitors are currently being tested for clinical use in the treatment of sporadic cancers (http://www.clinicaltrial.gov). Another example is metformin, an AMPK activator, FDA approved for the treatment of diabetes mellitus type 2. Population studies have shown that metformin treatment is associated with a significant reduction of neoplasms in general, and of breast and prostate cancer in particular (Papanas et al., 2010) . Metformin has also been suggested to serve as a candidate drug to treat PJSassociated lesions (Huang et al., 2008) . Although the requirement for intact LKB1 to activate AMPK upon stimulation with metformin is still under debate, it has been suggested that these drugs may only be effective to treat tumors that have retained one LKB1 allele intact (Lizcano et al., 2004; Shaw et al., 2005; Ouyang et al., 2010) .
The TSC1:TSC2 complex is the major direct effector of mTORC1 by regulation of Rheb. However, it has previously been shown that TSC1 and TSC2 bind multiple other proteins, suggesting that the functions of the TSC1:TSC2 complex are broader (Rosner et al., 2008) . This indicates that so far unknown effects of TSC mutations could affect the clinical phenotype of TSC patients. Additionally, these yet to be identified mediators involved in TSC1:TSC2 tumor suppressor function may be responsible for the differences in treatment efficiency. It should be investigated whether these yet undefined mediators are mTORC1 dependent.
Furthermore, the biological response (growth arrest versus apoptosis) of rapamycin is also known to depend on the oncogenic status of the cells, for example, rapamycin induces apoptosis in P53-deficient cells, whereas P53-proficient cells are resistant (Huang et al., 2003) . This is particularly important for the efficacy of rapamycin treatment of sporadic cancers as it is well known that P53 is mutated in more than half of all human sporadic cancers.
In conclusion, the impressive knowledge gained on the linear connections in signaling pathways provides targets that are useful for designing rationale therapy. However, the high levels of complexity in biological systems result in substantial unpredictability (compare for example, breast cancer (Kasper et al., 2009) ). In this 
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